Esperion Therapeutis.Inc. buy melinda
Start price
26.11.18
/
50%
€45.85
Target price
03.12.18
€53.22
Performance (%)
8.74%
End price
03.12.18
€49.85
Summary
This prediction ended on 03.12.18 with a price of €49.85. With a performance of 8.74%, the BUY prediction by melinda for Esperion Therapeutis.Inc. closed with a slight gain. melinda has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 5.214% | 5.214% | 43.118% | -89.307% |
| iShares Core DAX® | 4.094% | 4.888% | 17.421% | 22.413% |
| iShares Nasdaq 100 | 1.424% | -0.445% | 37.618% | 58.203% |
| iShares Nikkei 225® | -1.572% | -4.911% | 12.951% | 7.961% |
| iShares S&P 500 | 1.822% | 0.776% | 29.182% | 49.914% |
Comments by melinda for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 27/11 | 13:35 Présentation
Esperion Therapeutics, Inc. est une société pharmaceutique de stade clinique qui développe et commercialise des thérapies orales pour le traitement des patients présentant un cholestérol élevé à lipoprotéines de basse densité (LDL-C).
Il offre une augmentation des taux de C-LDL chez les patients atteints d’hypercholestérolémie, y compris chez les patients insuffisamment traités par les traitements modificateurs des lipides actuels.
Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer et Charles L. Bisgaier en mai 1998 et son siège social est situé à Ann Arbor, dans le Michigan.
Nombre d'employés : 57 personnes.
Stopped prediction by melinda for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€30.27
31.08.20
31.08.20
€35.00
04.11.21
04.11.21
-70.27%
09.10.21
09.10.21
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€41.49
01.11.18
01.11.18
€45.10
02.11.18
02.11.18
22.46%
02.11.18
02.11.18
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€36.13
04.05.18
04.05.18
€45.10
23.08.18
23.08.18
20.52%
23.08.18
23.08.18
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€69.33
08.03.18
08.03.18
€135.30
04.05.18
04.05.18
-47.63%
04.05.18
04.05.18
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€33.60
02.05.17
02.05.17
€36.53
21.06.17
21.06.17
9.07%
21.06.17
21.06.17
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€32.48
03.04.17
03.04.17
€36.08
12.04.17
12.04.17
5.78%
12.04.17
12.04.17